Cushing Syndrome clinical trials at UC Health
2 in progress, 1 open to eligible people
open to eligible people ages 18-80
This is a Phase 3, double-blind, placebo-controlled, randomized-withdrawal study to assess the efficacy, safety and pharmacokinetics (PK) of relacorilant in patients with endogenous Cushing syndrome and concurrent type 2 diabetes mellitus/impaired glucose tolerance and/or uncontrolled hypertension
Sorry, not currently recruiting here
This is a long-term, open-label extension study of levoketoconazole in subjects with endogenous Cushing's Syndrome.